

# Martin Thomas Strassnig, MD

Psychiatrist | Clinical Trials Specialist (CNS) | Forensic Psychiatry  
Aventura, FL | ABPN Board Certified | IMLC Multi-State Licensed

---

## INVESTMENT THESIS & DOMAIN EDGE

---

Board-certified psychiatrist with over two decades of academic, clinical, and contract research experience in CNS drug development. Evaluates therapeutic pipeline assets from dual vantage points: the clinical investigator who ran the trials and the quality oversight specialist who audits them. Applies empirical standards honed across 30+ sponsored studies to assess data integrity, endpoint credibility, regulatory pathway risk, and execution quality in Phase II-III psychiatric programs. Forensic practice adds independent expert judgment, evidentiary rigor, and the ability to perform skeptical, adversarial review of clinical claims.

## CLINICAL RESEARCH & PIPELINE EVALUATION

---

### Premier Research — Neuroscience Team, Clinical Quality Control

June 2019 – Present | Contract Research Organization (CRO)

- Cross-study quality oversight in CNS/psychiatry: pattern detection across sites, raters, and protocols in Phase II-III trials
- Macro-level signal analysis distinguishing systematic bias from random noise — rater drift, site-level outliers, protocol deviation clusters
- Expertise in rater reliability methodology; trained and evaluated clinical raters against ICH E6 and sponsor-defined standards
- Applies trial-execution knowledge to identify what sponsors underreport: missing safety signals, endpoint credibility gaps, enrollment quality issues
- CNS therapeutic areas: schizophrenia, bipolar disorder, cognitive impairment, Alzheimer's disease, Parkinson's disease, Tourette syndrome, tardive dyskinesia; substance use disorders

### Sponsored Clinical Trials — Principal and Site Investigator

2001 – 2018 | Academic Medical Centers: University of Pittsburgh, University of Toronto, University of Miami

- Principal Investigator or Site PI on 15+ industry-sponsored trials; Co-Investigator on 10+ additional studies
- Sponsors include: Novartis, Pfizer, J&J (Janssen), AstraZeneca, Bristol-Myers Squibb, Alkermes, Neurocrine Biosciences, Acadia, Biogen, Otsuka, Lundbeck, Axovant, Envivo, Genentech, Merck
- Phase II and III experience across antipsychotics, pro-cognitive agents, VMAT2 inhibitors, alpha-7 nAChR agonists, amyloid-targeting therapies, and alcohol use disorder
- NIMH Clinical Trials Network site participation (e-TENENTS, ACLAIMS, e-CAeSAR): NIH-funded comparative effectiveness and cognitive remediation programs
- IND-stage familiarity with regulatory milestones, primary/secondary endpoint selection, and FDA advisory patterns in CNS

## KEY CAPABILITIES FOR INVESTMENT DILIGENCE

---

- Pipeline risk assessment: identifies credibility gaps in Phase II readouts, NDA-stage vulnerabilities, and common execution failure modes in CNS trials
- Data integrity evaluation: experienced in detecting anomalies in clinical data packages — fabrication indicators, rater inflation, endpoint drift
- Regulatory pathway literacy: clinical hold triggers, REMS precedents, advisory committee dynamics in psychiatry and neurology

- Competitive landscape: deep familiarity with approved and pipeline agents across schizophrenia, depression, bipolar disorder, dementia, and movement disorders
- Independent expert judgment: forensic practice demands adversarial-level scrutiny of clinical evidence and causation claims — directly applicable to investment due diligence
- Key opinion leader network: active editorial relationships across Schizophrenia Bulletin, Neuropsychopharmacology, Journal of Clinical Psychopharmacology, and 15+ peer-reviewed journals

## CLINICAL PRACTICE

---

### Independent Telehealth Practice

February 2016 – Present

- 27,000+ completed visits; high-volume adult psychiatry across complex psychopharmacology, treatment-resistant conditions, and metabolic comorbidities
- Real-world prescribing experience provides ground-level signal on drug tolerability, patient adherence, and payer dynamics — context that Phase III data rarely captures

### Forensic Psychiatry — Independent Medical Examinations & Litigation Consulting

January 2022 – Present | Miami-Dade County Public Defender's Office & Private Referrals

- Personal injury and IME cases; scope structured to avoid pharmaceutical and product liability conflicts
- IMLC credentials enabling multi-state practice
- Forensic work demands independent evidentiary standards, resistance to advocacy bias, and systematic evaluation of clinical claims under adversarial conditions

## ACADEMIC APPOINTMENTS

---

**Adjunct Professor of Psychiatry** University of Miami, Miller School of Medicine | December 2022 – Present

Associate Professor of Psychiatry University of Miami | 2011 – 2016

Assistant Professor of Psychiatry University of Toronto / CAMH | 2009 – 2011

Assistant Professor of Psychiatry University of Pittsburgh / WPIC | 2007 – 2009

*Hospital leadership roles included: Medical Director (Inpatient Psychosis & Depression Units, University of Miami); Chief, rTMS and ECT Service; Associate Medical Director, South County Mental Health Center; Associate Director, Clinical and Translational Science Unit (FAU).*

## EDUCATION & TRAINING

---

**MD (Doctor of Medicine)** University of Graz, Austria | 1993 – 1999

Residency, Adult Psychiatry Western Psychiatric Institute and Clinic (UPMC) | 2003 – 2007

Residency, Adult Psychiatry Ludwig-Maximilians University Munich | 2001 – 2003

Visiting Research Fellow UPMC / WPIC | 2000 – 2001

## SELECTED PUBLICATIONS (59 PEER-REVIEWED ARTICLES, 15 BOOK CHAPTERS)

---

Publication record spans CNS pharmacology, cognitive outcomes in schizophrenia and bipolar disorder, metabolic comorbidities, functional disability, and Phase II-III clinical trial methodology. Peer reviewer for Schizophrenia Research, Schizophrenia Bulletin, Neuropsychopharmacology, Journal of Clinical Psychopharmacology, and 12 additional journals. Full list available on request.

**Representative:** Strassnig & Harvey. Cognition and disability in schizophrenia. World Psychiatry 2019. — Strassnig et al. Twenty-year BMI trajectory in schizophrenia and bipolar disorder. Bipolar Disorders 2017. — Strassnig et al. High velocity circuit resistance training improves cognition and psychiatric symptoms in severe mental illness. Psychiatry Research 2015.

## RECOGNITION

---

ISCTM Fellow International Society for CNS Clinical Trials and Methodology | 2012

NCDEU-NIMH New Investigator Award 2006

ASCP Award American Society for Clinical Psychopharmacology | 2006

APA Young Investigator Colloquium 2005

NARSAD Young Investigator Award USD 60,000 — Metabolic antecedents of insulin resistance in schizophrenia | 2009

NIMH R25 National Institutes of Mental Health, Research Training Grant | 2007-2009